Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial

WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a...
October 25, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials

HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
October 10, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors

Data to be Presented at Neuro-Oncology Annual Scientific Meeting HOUSTON, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
September 13, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson

Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center ...
August 13, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018

HOUSTON, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
August 09, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial

HOUSTON, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
July 31, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066

HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
July 18, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia

HOUSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
July 11, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover

HOUSTON, July 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
June 26, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Selected for the Russell Microcap Index

HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...